Related Experiment Video
Updated: Jul 26, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Ixazomib-induced Sweet's syndrome: A case report.
Jeanne Bellemare1, Hannah Laure El Fassy2, Alexandra Mereniuk1
1Division of Dermatology, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada.
Ixazomib, a proteasome inhibitor, can rarely cause Sweet's syndrome in multiple myeloma patients. This case highlights successful management with corticosteroids, allowing continued cancer treatment.
Area of Science:
- Oncology
- Dermatology
Background:
- Ixazomib is a proteasome inhibitor used for multiple myeloma.
- Sweet's syndrome is an uncommon adverse drug reaction.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Conditioned Taste Aversion
A notable characteristic of conditioned taste aversion is that it often requires only a single...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Oral Hypoglycemic Agents: Biguanides and Glitazones

